AbbVie is entering a new chapter of growth, fueled by its blockbuster immunology drugs and expanding neuroscience business. Investor Kevin Simpson shares why he's optimistic.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.